A narrative review examined the potential of Astragali Radix metabolites, which include polysaccharides, saponins, and flavonoids. These compounds are being studied for their effects on allergic asthma, allergic rhinitis, allergic conjunctivitis, and hypersensitivity pneumonitis. The analysis found that Astragali Radix and Astragalus polysaccharides exhibit anti-inflammatory, immunomodulatory, anti-airway remodeling, and anti-fibrotic activities. These findings establish a comprehensive foundation for the clinical application of Astragali Radix and the development of novel targeted therapeutics for allergic respiratory diseases.
The review did not report specific patient numbers, sample sizes, or follow-up periods. Safety data regarding adverse events, serious reactions, or discontinuations were also not reported in this document. Because the study is a narrative review rather than a clinical trial, it summarizes existing information rather than testing new treatments directly.
Readers should understand that this evidence supports further research and development but does not yet confirm that these metabolites work as a standard treatment. The main reason to be careful is that no specific dosages, safety profiles, or real-world outcomes were provided. This review helps guide future scientific work but is not a guide for immediate patient care.